troglitazone has been researched along with Icterus in 3 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Watkins, PB | 1 |
| Lewis, JH | 1 |
| Herrine, SK | 1 |
| Choudhary, C | 1 |
3 other studies available for troglitazone and Icterus
| Article | Year |
|---|---|
Idiosyncratic liver injury: challenges and approaches.
Topics: Adaptation, Physiological; Chemical and Drug Induced Liver Injury, Chronic; Chromans; Humans; Hypogl | 2005 |
'Hy's law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective.
Topics: Alanine Transaminase; Anticoagulants; Azetidines; Benzylamines; Bilirubin; Biomarkers; Chemical and | 2006 |
Severe hepatotoxicity associated with troglitazone.
Topics: Cholestasis; Chromans; Diabetes Mellitus, Type 1; Fatal Outcome; Female; Humans; Hypoglycemic Agents | 1999 |